RUMI, ELISA

RUMI, ELISA  

DIPARTIMENTO DI MEDICINA MOLECOLARE  

Mostra records
Risultati 1 - 20 di 184 (tempo di esecuzione: 0.04 secondi).
Titolo Data di pubblicazione Autore(i) File
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 1-gen-2017 Passamonti, F; Giorgino, T; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Caramazza, D; Merli, M; Pietra, D; Casalone, R; Rotunno, G; Barbui, T; Cazzola, M; Vannucchi, Am.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 1-gen-2008 Passamonti, Francesco; Rumi, Elisa; Caramella, M; Elena, Chiara; Arcaini, Luca; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, Paolo; Pascutto, C; Cazzola, Mario; Morra, E; Lazzarino, Mario
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 1-gen-2010 Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, Elisa; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, Mario; Cazzola, Mario; Tefferi, A.
A journey through infectious risk associated with ruxolitinib. 1-gen-2019 Sant'Antonio, E; Bonifacio, M; Breccia, M; Rumi, E
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 1-gen-2014 Lussana, F; Carobbio, A; Randi, Ml; Elena, Chiara; Rumi, Elisa; Finazzi, G; Bertozzi, I; Pieri, L; Ruggeri, M; Palandri, F; Polverelli, N; Elli, E; Tieghi, A; Iurlo, A; Ruella, M; Cazzola, Mario; Rambaldi, A; Vannucchi, Am; Barbui, T.
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 1-gen-2020 Rumi, Elisa
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 1-gen-2014 Rumi, Elisa; Harutyunyan, As; Casetti, I; Pietra, D; Nivarthi, H; Moriggl, R; Cleary, C; Bagienski, K; Astori, C; Bellini, M; Berg, T; Passamonti, F; Kralovics, R; Cazzola, Mario
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 1-gen-2014 Verstovsek, S; Passamonti, Francesco; Rambaldi, A; Barosi, G; Rosen, Pj; Rumi, Elisa; Gattoni, E; Pieri, L; Guglielmelli, P; Elena, Chiara; He, S; Contel, N; Mookerjee, B; Sandor, V; Cazzola, Mario; Kantarjian, Hm; Barbui, T; Vannucchi, A. M.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 1-gen-2022 Maffioli, M; Mora, B; Ball, S; Iurlo, A; Elli, Em; Finazzi, Mc; Polverelli, N; Rumi, E; Caramella, M; Carraro, Mc; D'Adda, M; Molteni, A; Sissa, C; Lunghi, F; Vismara, A; Ubezio, M; Guidetti, A; Caberlon, S; Anghilieri, M; Komrokji, R; Cattaneo, D; Della Porta, Mg; Giorgino, T; Bertù, L; Brociner, M; Kuykendall, A; Passamonti, F.
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 1-gen-2012 Passamonti, F; Thiele, J; Girodon, F; Rumi, Elisa; Carobbio, A; Gisslinger, H; Kvasnicka, Hm; Ruggeri, M; Randi, Ml; Gangat, N; Vannucchi, Am; Gianatti, A; Gisslinger, B; Müllauer, L; Rodeghiero, F; D'Amore, Es; Bertozzi, I; Hanson, Ca; Boveri, E; Marino, F; Maffioli, M; Caramazza, D; Antonioli, E; Carrai, V; Buxhofer Ausch, V; Pascutto, C; Cazzola, Mario; Barbui, T; Tefferi, A.
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 1-gen-2010 Passamonti, Francesco; Rumi, Elisa; Pietra, D; Elena, Chiara; Boveri, E; Arcaini, Luca; Roncoroni, E; Astori, C; Merli, M; Boggi, S; Pascutto, C; Lazzarino, Mario; Cazzola, Mario
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 1-gen-2013 Rumi, Elisa; Pietra, D; Guglielmelli, P; Bordoni, R; Casetti, I; Milanesi, C; Sant'Antonio, E; Ferretti, V; Pancrazzi, A; Rotunno, G; Severgnini, M; Pietrelli, A; Astori, C; Fugazza, E; Pascutto, C; Boveri, E; Passamonti, F; De Bellis, G; Vannucchi, A; Cazzola, Mario
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 1-gen-2021 Trotti, C; Sant'Antonio, E; Vanni, D; Casetti, Ic; Borsani, O; Pietra, D; Ferretti, Vv; Astori, C; Arcaini, L; Rumi, E.
Acute arterial and deep venous thromboembolism in COVID-19 patients: Risk factors and personalized therapy 1-gen-2020 Bozzani, A.; Arici, V.; Tavazzi, G.; Franciscone, M. M.; Danesino, V.; Rota, M.; Rossini, R.; Sterpetti, A. V.; Ticozzelli, G.; Rumi, E.; Mojoli, F.; Bruno, R.; Ragni, F.
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 1-gen-2017 Rumi, Elisa; Cazzola, Mario
Allelic imbalance in CALR somatic mutagenesis 1-gen-2015 Harutyunyan, As; Jäger, R; Chen, D; Berg, T; Rumi, Elisa; Gisslinger, B; Pietra, D; Gisslinger, H; Cazzola, Mario; Kralovics, R. 5.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 1-gen-2021 Barbui, T; De Stefano, V; Alvarez-Larran, A; Iurlo, A; Masciulli, A; Carobbio, A; Ghirardi, A; Ferrari, A; Cancelli, V; Elli, Em; Andrade-Campos, Mm; Kabat, Mg; Kiladjian, Jj; Palandri, F; Benevolo, G; Garcia-Gutierrez, V; Fox, Ml; Foncillas, Ma; Morcillo, Cm; Rumi, E; Osorio, S; Papadopoulos, P; Bonifacio, M; Cervantes, Ksq; Serrano, Ms; Carreno-Tarragona, G; Sobas, Ma; Lunghi, F; Patriarca, A; Elorza, Bn; Angona, A; Mazo, Em; Koschmieder, S; Carli, G; Cuevas, B; Hernandez-Boluda, Jc; Abadia, El; Cirici, Bx; Guglielmelli, P; Garrote, M; Cattaneo, D; Daffini, R; Cavalca, F; Bellosillo, B; Benajiba, L; Curto-Garcia, N; Bellini, M; Betti, S; Harrison, C; Rambaldi, A; Vannucchi, Am.
An insidious presentation of splenic marginal zone lymphoma 1-gen-2007 Burcheri, S; Arcaini, Luca; Della Porta, M; Paulli, Marco; Boveri, E; Zibellini, S; Rumi, Elisa; Algarotti, A; Passamouti, F; Lazzarino, M.
Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver 1-gen-2023 Bonometti, A; Borsani, O; Rumi, E; Ferretti, Vv; Dioli, C; Lucato, E; Paulli, M; Boveri, E.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 1-gen-2020 De Stefano, V; Ghirardi, A; Masciulli, A; Carobbio, A; Palandri, F; Vianelli, N; Rossi, E; Betti, S; Di Veroli, A; Iurlo, A; Cattaneo, D; Finazzi, G; Bonifacio, M; Scaffidi, L; Patriarca, A; Rumi, E; Casetti, Ic; Stephenson, C; Guglielmelli, P; Elli, Em; Palova, M; Rapezzi, D; Erez, D; Gomez, M; Wille, K; Perez-Encinas, M; Lunghi, F; Angona, A; Fox, Ml; Beggiato, E; Benevolo, G; Carli, G; Cacciola, R; Mcmullin, Mf; Tieghi, A; Recasens, V; Isfort, S; Marchetti, M; Griesshammer, M; Alvarez-Larran, A; Vannucchi, Am; Rambaldi, A; Barbui, T.